Granules India Limited — Investor Meet, 13-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Granules India reported robust Q2FY26 with revenue up 34% YoY to ₹1,297 Cr, driven by formulation sales in North America and Europe. PAT grew 34% YoY to ₹130.6 Cr, with EBITDA up 37% YoY to ₹278.2 Cr (21.5% margin), despite a ₹20 Cr loss from Ascelis Peptides. Gross margin expanded to 65.7% due to operational efficiency and product mix. R&D spend was ₹70.5 Cr. The company secured key regulatory approvals and GMP certifications, highlighting strong operational execution and a focus on strategic growth and R&D.